新一代血小板抑制剂——普拉格雷  

Prasugrel,a novel platelet inhibitor

作　　者：荆亚萍[1] 申东升[1] 熊维[1] 邓爵安[1] 

机构地区：[1]广东药学院药科学院/药物合成研究所,广东广州510006

出　　处：《国际药学研究杂志》2008年第5期373-376,共4页Journal of International Pharmaceutical Research

摘　　要：心血管疾病已严重危害人类健康,而血小板抑制剂可有效改善和预防心血管疾病,因此血小板抑制剂的研究已成为心血管疾病治疗的热点。新一代血小板P2Y12受体阻断剂普拉格雷,与噻氯匹啶、氯吡格雷相比,能更快速、更有效地抑制血小板聚集,是一种已处于Ⅲ期临床研究中的噻吩吡啶类药物。本文依据最新的文献报道,综述了血小板抑制剂的开发历程,以及普拉格雷的合成工艺和临床研究状况,同时对该药的临床应用前景进行了展望。At present, cardiovascular disease has seriously jeopardized the health of mankind, and platelet inhibitor can effectively improve and prevent this disease. Therefore, the study of platelet inhibitor has become the focus of the treatment of cardiovascular disease. Compared with ticlopidine and clopidogrel, prasugrel is a novel platelet P2Y12 receptor antagonist, whose inhibitory effects on platelet aggregation are more effective and rapid, and the present study of which has been in Ⅲ stage clinical trial. In this article, based on the recent studies in literature, we review the development course of platelet inhibitors, the synthesis of prasugrel and its clinical research. Meanwhile, the prospect of clinical application is also discussed.

关 键 词：心血管疾病 血小板聚集抑制剂 普拉格雷 

分 类 号：R972[医药卫生—药品]